Inhaled RNA Therapy: From Promise to Reality

Overview

Journal Trends Pharmacol Sci

Specialty Pharmacology

Date 2020 Sep 7

PMID 32893004

Citations 32

Authors

Michael Y T Chow

Yingshan Qiu

Jenny K W Lam

Affiliations

Soon will be listed here.

Abstract

RNA-based medicine is receiving growing attention for its diverse roles and potential therapeutic capacity. The largest obstacle in its clinical translation remains identifying a safe and effective delivery system. Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure. In this review, we highlight recent developments in pulmonary RNA delivery systems with the use of nonviral vectors. We also discuss the major knowledge gaps that require thorough investigation and provide insights that will help advance this exciting field towards the bedside.

Citing Articles

Robust peptide/RNA complexes prepared with microfluidic mixing for pulmonary delivery by nebulisation.

Ma C, Chow M, Zhang C, Goldbaum P, Hsieh J, Lam J Drug Deliv Transl Res. 2025; .

PMID: 39827227 DOI: 10.1007/s13346-024-01773-w.

Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination.

Liu S, Wen Y, Shan X, Ma X, Yang C, Cheng X Nat Commun. 2024; 15(1):9471.

PMID: 39488531 PMC: 11531489. DOI: 10.1038/s41467-024-53914-x.

Current status and trends in small nucleic acid drug development: Leading the future.

Miao Y, Fu C, Yu Z, Yu L, Tang Y, Wei M Acta Pharm Sin B. 2024; 14(9):3802-3817.

PMID: 39309508 PMC: 11413693. DOI: 10.1016/j.apsb.2024.05.008.

Aerosol Inhalation of Gene Delivery Therapy for Pulmonary Diseases.

Huang Y, Zhang J, Wang X, Jing H, Li H Biomolecules. 2024; 14(8).

PMID: 39199292 PMC: 11352762. DOI: 10.3390/biom14080904.

Recent Progress in Nucleic Acid Pulmonary Delivery toward Overcoming Physiological Barriers and Improving Transfection Efficiency.

Wang Q, Bu C, Dai Q, Chen J, Zhang R, Zheng X Adv Sci (Weinh). 2024; 11(18):e2309748.

PMID: 38460157 PMC: 11095210. DOI: 10.1002/advs.202309748.

References

Tashiro J, Rubio G, Limper A, Williams K, Elliot S, Ninou I . Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Front Med (Lausanne). 2017; 4:118. PMC: 5532376. DOI: 10.3389/fmed.2017.00118. View

Labiris N, Dolovich M . Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003; 56(6):588-99. PMC: 1884307. DOI: 10.1046/j.1365-2125.2003.01892.x. View

Habibovic A, Hristova M, Heppner D, Danyal K, Ather J, Janssen-Heininger Y . DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma. JCI Insight. 2016; 1(18):e88811. PMC: 5085603. DOI: 10.1172/jci.insight.88811. View

Moliva J, Rajaram M, Sidiki S, Sasindran S, Guirado E, Pan X . Molecular composition of the alveolar lining fluid in the aging lung. Age (Dordr). 2014; 36(3):9633. PMC: 4082594. DOI: 10.1007/s11357-014-9633-4. View

Dong J, Liao W, Peh H, Tan W, Zhou S, Wong W . Ribosomal Protein S3 Gene Silencing Protects Against Cigarette Smoke-Induced Acute Lung Injury. Mol Ther Nucleic Acids. 2018; 12:370-380. PMC: 6031153. DOI: 10.1016/j.omtn.2018.05.027. View

Garcia-Mouton C, Hidalgo A, Cruz A, Perez-Gil J . The Lord of the Lungs: The essential role of pulmonary surfactant upon inhalation of nanoparticles. Eur J Pharm Biopharm. 2019; 144:230-243. DOI: 10.1016/j.ejpb.2019.09.020. View

Miwata K, Okamoto H, Nakashima T, Ihara D, Horimasu Y, Masuda T . Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice. Mol Ther Nucleic Acids. 2018; 12:698-706. PMC: 6083018. DOI: 10.1016/j.omtn.2018.07.009. View

Gunasekara L, Al-Saiedy M, Green F, Pratt R, Bjornson C, Yang A . Pulmonary surfactant dysfunction in pediatric cystic fibrosis: Mechanisms and reversal with a lipid-sequestering drug. J Cyst Fibros. 2017; 16(5):565-572. DOI: 10.1016/j.jcf.2017.04.015. View

Agudelo C, Kumley B, Area-Gomez E, Xu Y, Dabo A, Geraghty P . Decreased surfactant lipids correlate with lung function in chronic obstructive pulmonary disease (COPD). PLoS One. 2020; 15(2):e0228279. PMC: 7004328. DOI: 10.1371/journal.pone.0228279. View

10.

Xu C, Tian H, Wang P, Wang Y, Chen X . The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA. Biomater Sci. 2016; 4(11):1646-1654. DOI: 10.1039/c6bm00601a. View

11.

Feldmann D, Xie Y, Jones S, Yu D, Moszczynska A, Merkel O . The impact of microfluidic mixing of triblock micelleplexes on in vitro / in vivo gene silencing and intracellular trafficking. Nanotechnology. 2017; 28(22):224001. PMC: 5539944. DOI: 10.1088/1361-6528/aa6d15. View

12.

Zhang D, Lee H, Wang X, Rai A, Groot M, Jin Y . Exosome-Mediated Small RNA Delivery: A Novel Therapeutic Approach for Inflammatory Lung Responses. Mol Ther. 2018; 26(9):2119-2130. PMC: 6127502. DOI: 10.1016/j.ymthe.2018.06.007. View

13.

Yan Y, Liu L, Xiong H, Miller J, Zhou K, Kos P . Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells. Proc Natl Acad Sci U S A. 2016; 113(39):E5702-10. PMC: 5047169. DOI: 10.1073/pnas.1606886113. View

14.

Lam J, Liang W, Chan H . Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev. 2011; 64(1):1-15. PMC: 7103329. DOI: 10.1016/j.addr.2011.02.006. View

15.

Merckx P, De Backer L, Van Hoecke L, Guagliardo R, Echaide M, Baatsen P . Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy. Acta Biomater. 2018; 78:236-246. DOI: 10.1016/j.actbio.2018.08.012. View

16.

Xie Y, Kim N, Nadithe V, Schalk D, Thakur A, Kilic A . Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release. 2016; 229:120-129. PMC: 4886848. DOI: 10.1016/j.jconrel.2016.03.029. View

17.

Serrano-Sevilla I, Artiga A, Mitchell S, Matteis L, de la Fuente J . Natural Polysaccharides for siRNA Delivery: Nanocarriers Based on Chitosan, Hyaluronic Acid, and Their Derivatives. Molecules. 2019; 24(14). PMC: 6680562. DOI: 10.3390/molecules24142570. View

18.

Choi M, Jeong H, Kim S, Kim M, Lee M, Rhim T . Targeted delivery of Chil3/Chil4 siRNA to alveolar macrophages using ternary complexes composed of HMG and oligoarginine micelles. Nanoscale. 2019; 12(2):933-943. DOI: 10.1039/c9nr06382j. View

19.

Boyd A, Guo S, Huang L, Kerem B, Oren Y, Walker A . New approaches to genetic therapies for cystic fibrosis. J Cyst Fibros. 2020; 19 Suppl 1:S54-S59. DOI: 10.1016/j.jcf.2019.12.012. View

20.

Li Z, Chen G, Ding L, Wang Y, Zhu C, Wang K . Increased Survival by Pulmonary Treatment of Established Lung Metastases with Dual STAT3/CXCR4 Inhibition by siRNA Nanoemulsions. Mol Ther. 2019; 27(12):2100-2110. PMC: 6904825. DOI: 10.1016/j.ymthe.2019.08.008. View